Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 20883512)

1.

Ranolazine safely decreases ventricular and atrial fibrillation in Timothy syndrome (LQT8).

Shah DP, Baez-Escudero JL, Weisberg IL, Beshai JF, Burke MC.

Pacing Clin Electrophysiol. 2012 Mar;35(3):e62-4. doi: 10.1111/j.1540-8159.2010.02913.x. Epub 2010 Sep 30.

PMID:
20883512
2.

The antiarrhythmic effects of ranolazine.

Foster NJ, Haines DE.

Rev Cardiovasc Med. 2009;10 Suppl 1:S38-45. Review.

PMID:
19898287
3.

Verapamil decreases ventricular tachyarrhythmias in a patient with Timothy syndrome (LQT8).

Jacobs A, Knight BP, McDonald KT, Burke MC.

Heart Rhythm. 2006 Aug;3(8):967-70. Epub 2006 Apr 29. No abstract available.

PMID:
16876748
4.

Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome.

Shimizu W, Ohe T, Kurita T, Kawade M, Arakaki Y, Aihara N, Kamakura S, Kamiya T, Shimomura K.

J Am Coll Cardiol. 1995 Nov 1;26(5):1299-309.

5.

Potential application of late sodium current blockade in the treatment of heart failure and atrial fibrillation.

Doshi D, Morrow JP.

Rev Cardiovasc Med. 2009;10 Suppl 1:S46-52. Review.

PMID:
19898288
6.

Ranolazine maintained sinus rhythm in a patient with refractory symptomatic atrial fibrillation.

Sossalla S, Sohns C, Seegers J, Lüthje L, Vollmann D, Zabel M.

Cardiovasc Ther. 2013 Oct;31(5):303-6. doi: 10.1111/1755-5922.12017.

PMID:
23205928
7.

New antiarrhythmic drugs for treatment of atrial fibrillation.

Dobrev D, Nattel S.

Lancet. 2010 Apr 3;375(9721):1212-23. doi: 10.1016/S0140-6736(10)60096-7. Epub 2010 Mar 22. Review.

PMID:
20334907
8.

Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart.

Carvas M, Nascimento BC, Acar M, Nearing BD, Belardinelli L, Verrier RL.

J Cardiovasc Pharmacol. 2010 Mar;55(3):286-91. doi: 10.1097/FJC.0b013e3181d26416.

PMID:
20075744
9.

Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation.

Verrier RL, Kumar K, Nieminen T, Belardinelli L.

Europace. 2013 Mar;15(3):317-24. doi: 10.1093/europace/eus380. Epub 2012 Dec 7. Review.

10.

Perspective: does ranolazine have potential for the treatment of atrial fibrillation?

Hancox JC, Doggrell SA.

Expert Opin Investig Drugs. 2010 Dec;19(12):1465-74. doi: 10.1517/13543784.2010.535517. Review.

PMID:
21105855
11.

Ranolazine for the prevention or treatment of atrial fibrillation: a systematic review.

Dagres N, Iliodromitis EK, Lekakis JP, Simitsis P, Karatzas D, Rallidis LS, Simeonidou E, Anastasiou-Nana M.

J Cardiovasc Med (Hagerstown). 2014 Mar;15(3):254-9. doi: 10.2459/JCM.0b013e328365b554. Review.

PMID:
24662415
12.

Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome.

Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L.

J Pharmacol Exp Ther. 2004 Aug;310(2):599-605. Epub 2004 Mar 18.

13.

Beta-adrenergic modulation of arrhythmogenesis and identification of targeted sites of antiarrhythmic therapy in Timothy (LQT8) syndrome: a theoretical study.

Sung RJ, Wu YH, Lai NH, Teng CH, Luo CH, Tien HC, Lo CP, Wu SN.

Am J Physiol Heart Circ Physiol. 2010 Jan;298(1):H33-44. doi: 10.1152/ajpheart.00232.2009. Epub 2009 Oct 23.

14.

Antiarrhythmic properties of ranolazine--from bench to bedside.

Tzeis S, Andrikopoulos G.

Expert Opin Investig Drugs. 2012 Nov;21(11):1733-41. doi: 10.1517/13543784.2012.716826. Epub 2012 Aug 23.

PMID:
22916846
15.

Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil.

Yoshiga Y, Shimizu A, Yamagata T, Hayano T, Ueyama T, Ohmura M, Itagaki K, Kimura M, Matsuzaki M.

Circ J. 2002 Nov;66(11):1024-8.

16.

Inhibition of late sodium current by mexiletine: a novel pharmotherapeutical approach in timothy syndrome.

Gao Y, Xue X, Hu D, Liu W, Yuan Y, Sun H, Li L, Timothy KW, Zhang L, Li C, Yan GX.

Circ Arrhythm Electrophysiol. 2013 Jun;6(3):614-22. doi: 10.1161/CIRCEP.113.000092. Epub 2013 Apr 11. Review.

17.

Ranolazine: an antianginal drug with antiarrhythmic properties.

Tamargo J, Caballero R, Delpón E.

Expert Rev Cardiovasc Ther. 2011 Jul;9(7):815-27. doi: 10.1586/erc.11.91. Review.

PMID:
21809962
18.

[New developments in the antiarrhythmic therapy of atrial fibrillation].

Simon H, Simon Demel K, Ritscher G, Turschner O, Brachmann J.

Herzschrittmacherther Elektrophysiol. 2010 Dec;21(4):212-6. doi: 10.1007/s00399-010-0093-y. Review. German.

PMID:
21107985
19.

A focus on antiarrhythmic properties of ranolazine.

Vizzardi E, D'Aloia A, Quinzani F, Bonadei I, Rovetta R, Bontempi L, Curnis A, Dei Cas L.

J Cardiovasc Pharmacol Ther. 2012 Dec;17(4):353-6. doi: 10.1177/1074248412442000. Epub 2012 Apr 6. Review.

PMID:
22492919
20.

Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.

Bunch TJ, Mahapatra S, Murdock D, Molden J, Weiss JP, May HT, Bair TL, Mader KM, Crandall BG, Day JD, Osborn JS, Muhlestein JB, Lappe DL, Anderson JL.

Pacing Clin Electrophysiol. 2011 Dec;34(12):1600-6. doi: 10.1111/j.1540-8159.2011.03208.x. Epub 2011 Sep 3.

PMID:
21895727
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk